Peak Bio's Strategic Merger With Akari Therapeutics
TipRanksMar 5 17:03 ET
Shareholder Alert: Ademi LLP Investigates Whether Peak Bio Inc. Has Obtained a Fair Price in Its Transaction With Akari
MILWAUKEE, March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari. Click here
PR NewswireMar 5 12:27 ET
Akari Therapeutics Rises on All Stock Deal With Peak Bio
Seeking AlphaMar 5 10:08 ET
Peak Stockholders Will Receive a Number of Akari Ordinary Shrs for Each Shr of Peak Stk They Own >AKTX
Peak Stockholders Will Receive a Number of Akari Ordinary Shrs for Each Shr of Peak Stk They Own >AKTX
Dow JonesMar 5 08:05 ET
Akari Therapeutics, Peak Bio: Hoyoung Huh, M.D., Ph.D. Expected to Serve as Chairman of Combined Entity >AKTX
Akari Therapeutics, Peak Bio: Hoyoung Huh, M.D., Ph.D. Expected to Serve as Chairman of Combined Entity >AKTX
Dow JonesMar 5 08:04 ET
Akari Therapeutics, Peak Bio: Post-merger Bd of Directors Will Consist of 3 Directors Selected by Each Co and 1 Independent Director Jointly Selected >AKTX
Akari Therapeutics, Peak Bio: Post-merger Bd of Directors Will Consist of 3 Directors Selected by Each Co and 1 Independent Director Jointly Selected >AKTX
Dow JonesMar 5 08:04 ET
Express News | Akari Therapeutics And Peak Bio Announce Merger Of Equals; Exchange Is Expected To Result In Implied Equity Ownership In The Combined Company Of Approximately 50% For Akari Shareholders And Approximately 50% For Peak Stockholders
Moomoo 24/7Mar 5 08:03 ET
Akari Therapeutics, Peak Bio Combined Entity Will Operate as Akari Therapeutics and Continue to Be Listed and Trade on Nasdaq Cap Market as AKTX >AKTX
Akari Therapeutics, Peak Bio Combined Entity Will Operate as Akari Therapeutics and Continue to Be Listed and Trade on Nasdaq Cap Market as AKTX >AKTX
Dow JonesMar 5 08:02 ET
Akari Therapeutics, Peak Bio to Merge as Equals in All-Stk Transaction >AKTX PKBO
Akari Therapeutics, Peak Bio to Merge as Equals in All-Stk Transaction >AKTX PKBO
Dow JonesMar 5 08:01 ET
Press Release: Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit BOSTON and PLEASANTON, Calif
Dow JonesMar 5 08:00 ET
Peak Bio Raises Over $2M Through Convertible Notes
TipRanksFeb 21 16:50 ET
Peak Bio Raises Capital via Convertible Promissory Notes
TipRanksFeb 7 04:39 ET
Peak Bio, Inc. Awarded Patent With Broad Coverage for Thailanstatin-ADC Platform Technology (PH-1) a Payload With Novel Immunomodulatory Effects That Target RNA Splicing
Peak Bio, Inc. (OTCQB) PK: PKBO) announced that it was awarded US Patent No. 11,691,982 B2 entitled "Thailanstatin Analogs" by The United States Patent and Trademark Office (USPTO).
GlobeNewswireJan 4 08:00 ET
Insider Buying: Hoyoung Huh Acquires 47,000 Shares of Peak Bio Inc (PKBO)
Yahoo FinanceSep 14, 2023 01:09 ET
Peak Bio(PKBO.US) 10% Shareholder Buys US$23,990.75 in Common Stocks
$Peak Bio(PKBO.US)$ 10% Shareholder Huh Hoyoung purchased 93,250 shares of Common Stocks on Aug 29, 30, 31, 2023 at an average price of $0.257 for a total value of $23,990.75.Source: Announcement What
moomoo NewsSep 1, 2023 16:47 ET
Peak Bio Up-lists to OTCQB Market
Seeking AlphaAug 31, 2023 12:59 ET
Peak Bio Appoints Michael Friedman, MBA as a Class III Director and as a Member of the Company's Audit Committee and Compensation Committee >PKBO
Peak Bio Appoints Michael Friedman, MBA as a Class III Director and as a Member of the Company's Audit Committee and Compensation Committee >PKBO
Dow JonesAug 31, 2023 08:02 ET
Peak Bio: Friedman Served as Senior Vice Pres at Ladenburg Thalmann & Co. Inc. Healthcare Investment Banking >PKBO
Peak Bio: Friedman Served as Senior Vice Pres at Ladenburg Thalmann & Co. Inc. Healthcare Investment Banking >PKBO
Dow JonesAug 31, 2023 08:02 ET
Analyzing Peak Bio (NASDAQ:PKBO) and Curis (NASDAQ:CRIS)
Peak Bio (NASDAQ:PKBO – Get Rating) and Curis (NASDAQ:CRIS – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the streng
Defense WorldMar 8, 2023 04:22 ET
Nasdaq to Delist Shares of Waitr and Calithera Biosciences, Among Others
Seeking AlphaMar 1, 2023 18:26 ET
No Data
No Data